Literature DB >> 35266906

The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma.

Arnav Srivastava1, Sai K Doppalapudi1, Hiren V Patel1, Ramaprasad Srinivasan2, Eric A Singer1.   

Abstract

PURPOSE OF REVIEW: The genomic and immunologic profiling of renal cell carcinoma (RCC) has provided the impetus for advancements in systemic treatments using combination therapy - either with immune check point inhibitor (ICI) + ICI or with ICI + targeted therapy. This approach has been examined in several landmark trials, treating both clear cell (ccRCC) and nonclear cell (nccRCC) histologies. In this review, we highlight systemic therapy advancements made in this new decade, the 2020s. RECENT
FINDINGS: Targeting the programmed death receptor 1/PD-L1 pathway has created more tolerable and effective immunotherapy regimens, expanding the applications of ICIs. These new applications, paired with trial data, include ICI monotherapy in nccRCC and adjuvant pembrolizumab in resected, high-risk RCC. In addition, ICI + ICI and ICI + TKI combination therapy have demonstrated oncologic efficacy in advanced ccRCC and sarcomatoid RCC. Similar progress has been noted regarding new targeted therapies. Along the hypoxia inducible factor pathway, belzutifan has received FDA approval in von Hippel-Lindau-associated RCC. In addition, in papillary RCC, agents such as cabozantinib target the MET proto-oncogene pathway and have demonstrated impressive oncologic outcomes.
SUMMARY: The 2020s utilize the molecular profiling of advanced RCC as a scaffold for recent trials in immunotherapy and targeted therapies. Going forward, emphasizing patient-reported outcomes and careful clinical trial construction remain critical to improve systemic therapy in RCC.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35266906      PMCID: PMC9177746          DOI: 10.1097/CCO.0000000000000831

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.915


  46 in total

1.  Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer.

Authors:  Arnav Srivastava; Zorimar Rivera-Núñez; Sinae Kim; Joshua Sterling; Nicholas J Farber; Kushan D Radadia; Hiren V Patel; Parth K Modi; Sharad Goyal; Rahul Parikh; Tina M Mayer; Biren Saraiya; Evita T Sadimin; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Cancer       Date:  2020-04-24       Impact factor: 6.860

2.  Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study.

Authors:  Ragnhild Hellesnes; Tor Åge Myklebust; Roy M Bremnes; Ása Karlsdottir; Øivind Kvammen; Helene F S Negaard; Torgrim Tandstad; Tom Wilsgaard; Sophie D Fosså; Hege S Haugnes
Journal:  J Clin Oncol       Date:  2020-12-23       Impact factor: 44.544

3.  Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Authors:  Nieves Martínez Chanzá; Wanling Xie; Mehmet Asim Bilen; Hannah Dzimitrowicz; Jarred Burkart; Daniel M Geynisman; Archana Balakrishnan; I Alex Bowman; Rohit Jain; Walter Stadler; Yousef Zakharia; Vivek Narayan; Benoit Beuselinck; Rana R McKay; Abhishek Tripathi; Russell Pachynski; Andrew W Hahn; JoAnn Hsu; Sumit A Shah; Elaine T Lam; Tracy L Rose; Anthony E Mega; Nicholas Vogelzang; Michael R Harrison; Amir Mortazavi; Elizabeth R Plimack; Ulka Vaishampayan; Hans Hammers; Saby George; Naomi Haas; Neeraj Agarwal; Sumanta K Pal; Sandy Srinivas; Benedito A Carneiro; Daniel Y C Heng; Dominick Bosse; Toni K Choueiri; Lauren C Harshman
Journal:  Lancet Oncol       Date:  2019-02-28       Impact factor: 41.316

4.  Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Authors:  Eric Jonasch; Frede Donskov; Othon Iliopoulos; W Kimryn Rathmell; Vivek K Narayan; Benjamin L Maughan; Stephane Oudard; Tobias Else; Jodi K Maranchie; Sarah J Welsh; Sanjay Thamake; Eric K Park; Rodolfo F Perini; W Marston Linehan; Ramaprasad Srinivasan
Journal:  N Engl J Med       Date:  2021-11-25       Impact factor: 176.079

5.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Authors:  W Marston Linehan; Paul T Spellman; Christopher J Ricketts; Chad J Creighton; Suzanne S Fei; Caleb Davis; David A Wheeler; Bradley A Murray; Laura Schmidt; Cathy D Vocke; Myron Peto; Abu Amar M Al Mamun; Eve Shinbrot; Anurag Sethi; Samira Brooks; W Kimryn Rathmell; Angela N Brooks; Katherine A Hoadley; A Gordon Robertson; Denise Brooks; Reanne Bowlby; Sara Sadeghi; Hui Shen; Daniel J Weisenberger; Moiz Bootwalla; Stephen B Baylin; Peter W Laird; Andrew D Cherniack; Gordon Saksena; Scott Haake; Jun Li; Han Liang; Yiling Lu; Gordon B Mills; Rehan Akbani; Mark D M Leiserson; Benjamin J Raphael; Pavana Anur; Donald Bottaro; Laurence Albiges; Nandita Barnabas; Toni K Choueiri; Bogdan Czerniak; Andrew K Godwin; A Ari Hakimi; Thai H Ho; James Hsieh; Michael Ittmann; William Y Kim; Bhavani Krishnan; Maria J Merino; Kenna R Mills Shaw; Victor E Reuter; Ed Reznik; Carl S Shelley; Brian Shuch; Sabina Signoretti; Ramaprasad Srinivasan; Pheroze Tamboli; George Thomas; Satish Tickoo; Kenneth Burnett; Daniel Crain; Johanna Gardner; Kevin Lau; David Mallery; Scott Morris; Joseph D Paulauskis; Robert J Penny; Candace Shelton; W Troy Shelton; Mark Sherman; Eric Thompson; Peggy Yena; Melissa T Avedon; Jay Bowen; Julie M Gastier-Foster; Mark Gerken; Kristen M Leraas; Tara M Lichtenberg; Nilsa C Ramirez; Tracie Santos; Lisa Wise; Erik Zmuda; John A Demchok; Ina Felau; Carolyn M Hutter; Margi Sheth; Heidi J Sofia; Roy Tarnuzzer; Zhining Wang; Liming Yang; Jean C Zenklusen; Jiashan Zhang; Brenda Ayala; Julien Baboud; Sudha Chudamani; Jia Liu; Laxmi Lolla; Rashi Naresh; Todd Pihl; Qiang Sun; Yunhu Wan; Ye Wu; Adrian Ally; Miruna Balasundaram; Saianand Balu; Rameen Beroukhim; Tom Bodenheimer; Christian Buhay; Yaron S N Butterfield; Rebecca Carlsen; Scott L Carter; Hsu Chao; Eric Chuah; Amanda Clarke; Kyle R Covington; Mahmoud Dahdouli; Ninad Dewal; Noreen Dhalla; Harsha V Doddapaneni; Jennifer A Drummond; Stacey B Gabriel; Richard A Gibbs; Ranabir Guin; Walker Hale; Alicia Hawes; D Neil Hayes; Robert A Holt; Alan P Hoyle; Stuart R Jefferys; Steven J M Jones; Corbin D Jones; Divya Kalra; Christie Kovar; Lora Lewis; Jie Li; Yussanne Ma; Marco A Marra; Michael Mayo; Shaowu Meng; Matthew Meyerson; Piotr A Mieczkowski; Richard A Moore; Donna Morton; Lisle E Mose; Andrew J Mungall; Donna Muzny; Joel S Parker; Charles M Perou; Jeffrey Roach; Jacqueline E Schein; Steven E Schumacher; Yan Shi; Janae V Simons; Payal Sipahimalani; Tara Skelly; Matthew G Soloway; Carrie Sougnez; Angela Tam; Donghui Tan; Nina Thiessen; Umadevi Veluvolu; Min Wang; Matthew D Wilkerson; Tina Wong; Junyuan Wu; Liu Xi; Jane Zhou; Jason Bedford; Fengju Chen; Yao Fu; Mark Gerstein; David Haussler; Katayoon Kasaian; Phillip Lai; Shiyun Ling; Amie Radenbaugh; David Van Den Berg; John N Weinstein; Jingchun Zhu; Monique Albert; Iakovina Alexopoulou; Jeremiah J Andersen; J Todd Auman; John Bartlett; Sheldon Bastacky; Julie Bergsten; Michael L Blute; Lori Boice; Roni J Bollag; Jeff Boyd; Erik Castle; Ying-Bei Chen; John C Cheville; Erin Curley; Benjamin Davies; April DeVolk; Rajiv Dhir; Laura Dike; John Eckman; Jay Engel; Jodi Harr; Ronald Hrebinko; Mei Huang; Lori Huelsenbeck-Dill; Mary Iacocca; Bruce Jacobs; Michael Lobis; Jodi K Maranchie; Scott McMeekin; Jerome Myers; Joel Nelson; Jeremy Parfitt; Anil Parwani; Nicholas Petrelli; Brenda Rabeno; Somak Roy; Andrew L Salner; Joel Slaton; Melissa Stanton; R Houston Thompson; Leigh Thorne; Kelinda Tucker; Paul M Weinberger; Cynthia Winemiller; Leigh Anne Zach; Rosemary Zuna
Journal:  N Engl J Med       Date:  2015-11-04       Impact factor: 91.245

6.  Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup.

Authors:  Eric A Singer; Srinivas Vourganti; Kelly Y Lin; Gopal N Gupta; Peter A Pinto; Ardeshir R Rastinehad; W Marston Linehan; Gennady Bratslavsky
Journal:  J Urol       Date:  2012-10-18       Impact factor: 7.450

7.  Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Authors:  Robert J Motzer; Alain Ravaud; Jean-Jacques Patard; Hardev S Pandha; Daniel J George; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Michelle Casey; Lucile Serfass; Allan J Pantuck; Michael Staehler
Journal:  Eur Urol       Date:  2017-09-28       Impact factor: 20.096

8.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Konstantin Penkov; John Haanen; Brian Rini; Laurence Albiges; Matthew T Campbell; Balaji Venugopal; Christian Kollmannsberger; Sylvie Negrier; Motohide Uemura; Jae L Lee; Aleksandr Vasiliev; Wilson H Miller; Howard Gurney; Manuela Schmidinger; James Larkin; Michael B Atkins; Jens Bedke; Boris Alekseev; Jing Wang; Mariangela Mariani; Paul B Robbins; Aleksander Chudnovsky; Camilla Fowst; Subramanian Hariharan; Bo Huang; Alessandra di Pietro; Toni K Choueiri
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

Review 9.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

10.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Authors:  Robert Motzer; Boris Alekseev; Sun-Young Rha; Camillo Porta; Masatoshi Eto; Thomas Powles; Viktor Grünwald; Thomas E Hutson; Evgeny Kopyltsov; María J Méndez-Vidal; Vadim Kozlov; Anna Alyasova; Sung-Hoo Hong; Anil Kapoor; Teresa Alonso Gordoa; Jaime R Merchan; Eric Winquist; Pablo Maroto; Jeffrey C Goh; Miso Kim; Howard Gurney; Vijay Patel; Avivit Peer; Giuseppe Procopio; Toshio Takagi; Bohuslav Melichar; Frederic Rolland; Ugo De Giorgi; Shirley Wong; Jens Bedke; Manuela Schmidinger; Corina E Dutcus; Alan D Smith; Lea Dutta; Kalgi Mody; Rodolfo F Perini; Dongyuan Xing; Toni K Choueiri
Journal:  N Engl J Med       Date:  2021-02-13       Impact factor: 91.245

View more
  4 in total

Review 1.  Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.

Authors:  James A McCubrey; Li V Yang; Stephen L Abrams; Linda S Steelman; Matilde Y Follo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Giuseppa Augello; Melchiorre Cervello
Journal:  Cells       Date:  2022-07-09       Impact factor: 7.666

Review 2.  Role of metastasectomy in the management of renal cell carcinoma.

Authors:  Mark Mikhail; Kevin J Chua; Labeeqa Khizir; Alexandra Tabakin; Eric A Singer
Journal:  Front Surg       Date:  2022-07-29

3.  The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.

Authors:  Huiyang Yuan; Xin Qin; Jing Wang; Qingya Yang; Yidong Fan; Dawei Xu
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

4.  Development and validation of a novel necroptosis-related score to improve the outcomes of clear cell renal cell carcinoma.

Authors:  Ji Chen; Qiqi Tao; Zhichao Lang; Yan Jin; Guanqi Chen; Xinling Li; Zhixian Yu; Yeping Li
Journal:  Front Genet       Date:  2022-09-12       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.